Biologics Inc., a McKesson Specialty Health company, has been selected by Takeda Pharmaceutical Co. to be a “specialty pharmacy provider” for ALUNBRIG, a Takeda-manufactured drug for anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC).
“We are thrilled to have been given the privilege of being in this network of specialty pharmacies dispensing ALUNBRIG,” Biologics Vice President Brandon Tom said. “Our team has decades of experience supporting NSCLC patients. We’re well prepared to help patients transition to this new therapy and to support them throughout their entire treatment journey.”
Biologics Inc. was approved by the U.S. Food and Drug Administration last month for patients who have “progressed on or are intolerant to crizotinib,” a press release said. “Biologics brings efficiency and humanity to oncology care management by focusing on the patient’s best interest as the surest path to managing cost and risk.”
Patients who suffer from NSCLC make up about 85 percent of lung cancer cases in the U.S. Biologics’ works to develop individualized plans with a multidisciplinary team for those patients who have unique needs.
If physicians want to submit prescriptions, they are welcome to do so via phone (800-850-4306), fax (800-823-4506) or eScribe.
Alerts Sign-up